10-Q: EBR Systems Reports Q3 Loss Amid WiSE CRT System Launch

EBR Systems, Inc. reported an increased net loss for the third quarter and first nine months of 2025 despite commencing commercial sales of its FDA-approved WiSE CRT System and securing significant capital.

Summary

• Net loss for Q3 2025 increased by 21.2% to $12.2 million, compared to $10.1 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, increased by 13.1% to $34.7 million, compared to $30.7 million in the same period of 2024.
• Generated first-time revenue of $512,093 in Q3 2025 and $681,797 for the nine months ended September 30, 2025, following FDA approval of the WiSE CRT System in April 2025.
• Gross margin was 43.8% for Q3 2025 and 45.2% for the nine months, positively impacted by the use of previously expensed inventory; excluding this, gross margin would have been negative 25.3% and 31.9% respectively.
• Selling, General and Administrative (SG&A) expenses significantly increased by 103.6% in Q3 2025 to $5.9 million and by 86.1% for the nine months to $15.5 million, driven by sales and marketing expansion.
• Research and Development (R&D) expenses decreased by 0.9% in Q3 2025 to $6.2 million and by 12.7% for the nine months to $17.6 million, primarily due to reduced contract manufacturing and facility costs, partially offset by increased personnel and clinical expenses.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $73.0 million as of September 30, 2025.
• Secured $46.2 million in net proceeds from institutional placement and a rights offering in May and June 2025.
• Commenced commercial implants at four new U.S. hospitals in Q3 2025, bringing the total to seven active Limited Market Release (LMR) hospitals for the nine months ended September 30, 2025.

Sentiment

Score: 4

Explanation: While the company achieved a significant milestone with FDA approval and generated its first revenue, the substantial increase in net loss and operating cash burn, coupled with a negative gross margin (excluding expensed inventory), indicates significant challenges in scaling commercialization profitably. The capital raise provides a temporary buffer, but the path to profitability remains long and uncertain, with significant risks ahead.

Positives

• Achieved first-time revenue of $512,093 in Q3 2025 and $681,797 for the nine months ended September 30, 2025, following FDA approval of the WiSE CRT System.
• Successfully raised $46.2 million in net proceeds from an institutional placement and a non-underwritten rights offering in May and June 2025, strengthening liquidity.
• FDA approval for commercial distribution of the WiSE CRT System was received on April 11, 2025, enabling market entry.
• CMS approved New Technology Add-On Payment (NTAP) for WiSE, commencing October 1, 2025, securing 65% reimbursement of the cost.
• Preliminary approval for Transitional Pass-Through (TPT) reimbursement scheme for WiSE, commencing October 1, 2025, effective for three years, covering outpatient settings.
• Working capital increased to $71.9 million as of September 30, 2025, from $64.5 million at December 31, 2024.
• Existing cash, cash equivalents, and marketable securities, along with projected revenue, are believed to be sufficient to fund operations for at least the next 12 months.
• R&D expenses decreased by 12.7% for the nine months ended September 30, 2025, indicating some cost efficiency in development.

Negatives

• Net loss increased by 21.2% to $12.2 million in Q3 2025 and by 13.1% to $34.7 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Selling, General and Administrative (SG&A) expenses increased significantly by 103.6% in Q3 2025 and 86.1% for the nine months, reflecting substantial investment in commercialization efforts that are yet to yield proportional revenue.
• Negative gross margin of 25.3% for Q3 2025 and 31.9% for the nine months, when excluding the use of previously expensed inventory, indicates high production costs relative to current sales prices.
• Net cash used in operating activities increased by $7.9 million to $38.2 million for the nine months ended September 30, 2025, highlighting continued cash burn.
• Shift from net cash provided by investing activities ($22.3 million in 2024) to net cash used ($0.3 million in 2025) for the nine-month period, primarily due to increased marketable securities purchases and property/equipment.
• The company has incurred operating losses and negative cash flows from operations since inception and anticipates these conditions to continue in the foreseeable future.
• Accumulated deficit reached $388.2 million as of September 30, 2025.

Risks

• Failure to meet enrollment requirements or complete the required post-marketing study for the WiSE CRT System to the satisfaction of the FDA could result in withdrawal of WiSE's application approval.
• Results of the post-marketing study may lead to additional warnings or precautions for the WiSE CRT System label, expose additional safety concerns, or result in product liability, reputational damage, or product withdrawal.
• Changes in economic conditions, domestic and foreign trade policies, monetary policies, and other factors beyond the company's control may adversely impact business, operations, and financial condition.
• The current international trade and regulatory environment is subject to significant ongoing uncertainty, including new tariffs, retaliatory measures, and non-tariff barriers, which could affect the medical device industry.
• Trade disputes, tariffs, restrictions, and other political tensions may exacerbate unfavorable macroeconomic conditions such as inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions.
• The commercial potential and ability to successfully commercialize WiSE is unproven and requires effective sales, marketing, manufacturing, distribution, information systems, and pricing strategies, as well as regulatory compliance.
• Growth depends on market acceptance and wide adoption of WiSE by physicians and hospital staff, which requires increasing awareness and demand.
• The rate of sales force growth and effectiveness of new hires can impact revenue growth and costs.
• Intense competition from large, well-capitalized companies with existing and future products and marketing resources.
• The level of reimbursement from third-party payors for procedures using WiSE could substantially impact pricing and product acceptance.
• The company's ability to support long-term working capital and capital expenditure requirements depends on many factors, including clinical trial results, regulatory reviews, R&D costs, sales and marketing capabilities, and global economic conditions.
• Inability to raise additional equity or debt financing on acceptable terms, or at all, if current and anticipated future liquidity sources are insufficient.

Future Outlook

The company anticipates continued net losses and negative cash flows from operations in the foreseeable future. It expects to fund operations for at least the next 12 months using existing cash, cash equivalents, marketable securities, and projected revenue from the WiSE CRT System in the U.S. The full market release strategy includes expanding market presence, scaling the field team, and broadening into additional hospitals. International commercial activities will commence upon obtaining regulatory approvals and payment coverage in target markets like Australia, the UK, and the EU. A post-marketing study for WiSE is scheduled to begin enrollment in November 2025 and conclude in December 2027.

Management Comments

• "We have implemented a Limited Market Release (LMR), with the following objectives: Initial Target Accounts, Expansion and Optimization, and Increase Implants Per Site."
• "Our full market release strategy includes expanding market presence and maximizing product adoption, utilizing refined business operations, and continuing scaling the field team."
• "Our OUS commercial activities will not commence until we obtain regulatory approvals and certification in select, target markets."
• "Based on our current operating plans and assumptions we believe that our existing cash, cash equivalents, and current and noncurrent marketable securities, together with projected revenue from the U.S of the WiSE CRT System will be sufficient to fund our projected operating requirements for at least the next 12 months from the date of this filing."

Industry Context

EBR Systems operates in the highly competitive medical device industry, specifically within cardiac rhythm management (CRM). The WiSE CRT System represents a novel, leadless approach to cardiac resynchronization therapy, addressing a key shortcoming of traditional lead-based systems. The company's recent FDA approval and securing of NTAP and TPT reimbursement codes are critical steps for market penetration in the U.S., aligning with industry trends towards innovative, less invasive solutions and favorable reimbursement for breakthrough devices. However, the company faces competition from large, established players and the challenge of driving adoption for a new technology.

Corporate Governance

Legal Proceedings

• Management believes that the probability of a material loss with respect to any currently pending legal proceeding is remote. Litigation is inherently uncertain and could have an adverse impact due to defense/settlement costs and diversion of management resources.

Related Party Transactions

• Dr. Bronwyn Evans, a member of the Board of Directors, participated in the June 2025 Securities Purchase Plan, purchasing 30,000 CDIs for $19,293.

Stakeholder Impact

• Shareholders: Dilution from recent capital raises (institutional placement and rights offering). Potential for future dilution if additional financing is required. Continued net losses and negative cash flow impact shareholder equity. FDA approval and reimbursement pathways offer long-term growth potential.
• Employees: Workforce expansion in sales and marketing. Increased personnel-related expenses. New 401(k) matching contributions enhance benefits. Stock-based compensation continues to be a significant component of overall compensation.
• Customers (Hospitals/Medical Facilities): Access to the newly FDA-approved WiSE CRT System. Benefit from NTAP and TPT reimbursement schemes starting October 1, 2025, which should cover device costs.
• Suppliers/Creditors: Company has significant purchase commitments ($12.1 million non-cancelable). Debt obligations to Runway Growth Finance Corp. ($41.8 million outstanding). Compliance with debt covenants is maintained.

Next Steps

• Expand market presence and maximize product adoption for WiSE.
• Continue scaling the field team for sales and marketing.
• Expand into additional high-volume hospitals or medical facilities in the U.S.
• Obtain regulatory approvals and certification in select international target markets (Australia, UK, EU) for OUS commercial activities.
• Secure appropriate payment coverage for WiSE in OUS markets.
• Begin enrollment for the prospective, real-world, observational post-marketing study for WiSE in November 2025.
• Complete the post-marketing study by December 2027, with patient monitoring for up to five years post-implant.
• Complete tenant improvements for the new Santa Clara facility during the first quarter of 2026.
• Continue to advance the research and development of the WiSE CRT system.
• Develop, establish, and validate commercial-scale current good manufacturing practice (cGMP).
• Pursue payor coverage and reimbursement for current and future product candidates.
• Maintain, expand, and protect intellectual property portfolio.

Key Dates

Recommendation

EBR Systems has achieved a critical milestone with FDA approval for its WiSE CRT System and has begun commercialization, generating its first revenue. The securing of NTAP and TPT reimbursement codes is a significant positive, de-risking adoption for hospitals. However, the company's financial performance shows a substantial increase in net losses and operating cash burn, driven by aggressive sales and marketing expansion. The reported gross margin, when adjusted for previously expensed inventory, is negative, indicating high current production costs relative to sales. While the recent capital raise provides liquidity for the next 12 months, the path to sustainable profitability is long and uncertain, with significant execution risks in market acceptance, sales force effectiveness, and post-marketing study compliance. Given the early stage of commercialization and the high cash burn, a 'hold' recommendation is appropriate. Investors should monitor the pace of WiSE adoption, improvements in gross margin, and the company's ability to control operating expenses as it scales.

Keywords

EBR Systems, WiSE CRT System, Cardiac Resynchronization Therapy, Medical Device, FDA Approval, 10-Q, Financial Results, Net Loss, Revenue, Commercialization, Healthcare Technology, Implantable Device, Cardiology, ASX, NTAP, TPT, Capital Raise